Weekly Recap: Papzimeos FDA approval and Analyst Buy with $12 target

Precigen Inc (NASDAQ:PGEN) is shifting from clinical-stage to commercial launch after FDA approval of Papzimeos for recurrent respiratory papillomatosis, while an analyst initiated Buy coverage with a $12 target, citing upside from pipeline assets PRGN-2009, AdenoVerse and UltraCAR-T.Previous Week…